Posted by Michael Wonder on 24 Jan 2022
FDA approves Nucala (mepolizumab) 40 mg pre-filled syringe for children with severe eosinophilic asthma
24 January 2022 - This approval allows for at home administration in patients 6-11 years old with severe eosinophilic asthma.
GlaxoSmithKline today announced that the US FDA has approved a 40 mg pre-filled syringe of Nucala (mepolizumab) for appropriate children aged 6 to 11 years old who have severe eosinophilic asthma.
